Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.

Journal of acquired immune deficiency syndromes (1999) - 1 May 2017

Ray Neelanjana, Li Tianbo, Lin Zeyu, Protack Tricia, van Ham Petronella Maria, Hwang Carey, Krystal Mark, Nijhuis Monique, Lataillade Max, Dicker Ira

Abstract excerpt

BACKGROUND: Protease inhibitor (PI)-resistant HIV-1 isolates with primary substitutions in protease (PR) and secondary substitutions in Gag could potentially exhibit cross-resistance to maturation inhibitors. We evaluated the second-generation maturation inhibitor, GSK3532795, for activity toward clinical isolates with genotypic and phenotypic characteristics associated with PI resistance (longitudinal). METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to gag Gene Products, Human Immunodeficiency Virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotyping Techniques

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Inhibitory Concentration 50

Share to Longitudinal Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 28234686
DOI: 10.1097/QAI.0000000000001304
PMCID: PMC5389583

Genes

CFB

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates.PMID 28234686Read ↗

Human Immunodeficiency Virus Gag and protease: partners in resistance.Semantic proximity Read ↗

HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Semantic proximity Read ↗

Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C.Semantic proximity Read ↗

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.Semantic proximity Read ↗

Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes.Semantic proximity Read ↗

Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.Semantic proximity Read ↗

Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.Semantic proximity Read ↗

In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.Semantic proximity Read ↗

Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy.Semantic proximity Read ↗

Phenotypic Characterization of Replication‐Impaired Lenacapavir‐Resistant HIV Clinical IsolatesSemantic proximity Read ↗

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.Semantic proximity Read ↗

New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion MaturationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.